{'fraction_non_alphanumeric': 0.03694581280788178, 'fraction_numerical': 0.0361247947454844, 'mean_word_length': 4.804761904761905, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
111In-hyaluronectin, a new probe for radiodetection of tumours: biodistribution and imaging in grafted mice.

Hyaluronectin (HN), a glycoprotein which shows a strong specific affinity for Hyaluronic Acid (HA), a very high molecular weight glycosaminoglycan expressed in the stroma reaction of all tumours, was used to radiolocalize grafted autologous carcinomas (CB33 and CB03) in mice. After conjugation to DTPA (0.5-3.7 DTPA/HN) and radiolabelling with 111In (5 microCi/micrograms HN) HN retained 93% of its affinity for HA. Different preparations of HN purified from lamb brain were assayed. The best results were obtained when the HN molecules reactive with HA were selected by gel permeation to discard unreactive molecules which were unable to complex with HA. At 48 hours the tumour to blood ratio was 7.7 with a localization index of 2.2 in CB33; there was 2.8% uptake of the injected dose (ID) into CB33 and 1.6% into CB03. 111In-HN uptake per gram of tumour was tumour-size dependent: the smaller masses had the higher uptake. Tumours were visualized and either early images of 111In-HN distribution or simultaneous distribution images of 99mTc-phytate or 201Tl-DTPA were used for the subtraction treatments.